de Roij van Zuijdewijn Camiel L M, Chapdelaine Isabelle, Nubé Menso J, Blankestijn Peter J, Bots Michiel L, Konings Constantijn J A M, Kremer Hovinga Ton K, Molenaar Femke M, van der Weerd Neelke C, Grooteman Muriel P C
Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.
Institute for Cardiovascular Research VU University Medical Center (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands.
Clin Kidney J. 2017 Dec;10(6):804-812. doi: 10.1093/ckj/sfw140. Epub 2017 Feb 15.
Available evidence suggests a reduced mortality risk for patients treated with high-volume postdilution hemodiafiltration (HDF) when compared with hemodialysis (HD) patients. As the magnitude of the convection volume depends on treatment-related factors rather than patient-related characteristics, we prospectively investigated whether a high convection volume (defined as ≥22 L/session) is feasible in the majority of patients (>75%). A multicenter study was performed in adult prevalent dialysis patients. Nonparticipating eligible patients formed the control group. Using a stepwise protocol, treatment time (up to 4 hours), blood flow rate (up to 400 mL/min) and filtration fraction (up to 33%) were optimized as much as possible. The convection volume was determined at the end of this optimization phase and at 4 and 8 weeks thereafter. Baseline characteristics were comparable in participants ( = 86) and controls ( = 58). At the end of the optimization and 8 weeks thereafter, 71/86 (83%) and 66/83 (80%) of the patients achieved high-volume HDF (mean 25.5 ± 3.6 and 26.0 ± 3.4 L/session, respectively). While treatment time remained unaltered, mean blood flow rate increased by 27% and filtration fraction increased by 23%. Patients with <22 L/session had a higher percentage of central venous catheters (CVCs), a shorter treatment time and lower blood flow rate when compared with patients with ≥22 L/session. High-volume HDF is feasible in a clear majority of dialysis patients. Since none of the patients agreed to increase treatment time, these findings indicate that high-volume HDF is feasible just by increasing blood flow rate and filtration fraction.
现有证据表明,与接受血液透析(HD)的患者相比,接受高容量后稀释血液透析滤过(HDF)治疗的患者死亡风险降低。由于对流体积的大小取决于治疗相关因素而非患者相关特征,我们前瞻性地研究了高对流体积(定义为≥22 L/次治疗)在大多数患者(>75%)中是否可行。在成年维持性透析患者中进行了一项多中心研究。未参与的符合条件的患者组成对照组。采用逐步方案,尽可能优化治疗时间(最长4小时)、血流速度(最高400 mL/分钟)和滤过分数(最高33%)。在该优化阶段结束时以及此后4周和8周时测定对流体积。参与者(n = 86)和对照组(n = 58)的基线特征具有可比性。在优化阶段结束时以及此后8周时,分别有71/86(83%)和66/83(80%)的患者实现了高容量HDF(平均分别为25.5±3.6和26.0±3.4 L/次治疗)。虽然治疗时间保持不变,但平均血流速度增加了27%,滤过分数增加了23%。与对流体积≥22 L/次治疗的患者相比,对流体积<22 L/次治疗的患者中心静脉导管(CVC)的比例更高、治疗时间更短且血流速度更低。高容量HDF在绝大多数透析患者中是可行的。由于没有患者同意增加治疗时间,这些发现表明,仅通过提高血流速度和滤过分数,高容量HDF就是可行的。